Abstract:Biomarker from blood could be a useful and non-invasive tool to provide real-time information in the procedure of treatment. To further understand the role of plasma mRNA in chemo-efficiency prediction, several mRNA levels were assessed in plasma and paired FFPE tumor tissues, and were correlated with chemosensitivity. In the 133 patients with locally advanced gastric cancer (Stage III), significant correlations were observed between plasma and tumor mRNA levels of BRCA1(rho = 0.532, P < 0.001), ERCC1(rho = 0.570, P < 0.001), TS(rho = 0.506, P = 0.002), Topo1 (rho = 0.310, P = 0.031), and APTX (rho = 0.561, P < 0.001). Correlations were also observed between the mRNA expression of plasma/tumor BRCA1 levels and docetaxel sensitivity (P < 0.001), plasma/tumor TS and pemetrexed sensitivity (P < 0.001), plasma/tumor BRCA1 and platinum sensitivity (plasma, P = 0.016; tumor, P < 0.001), and plasma/tumor Topo1 and irinotecan sensitivity (plasma, P = 0.015; tumor, P = 0.011). Among another 64 patients with advanced cancer (Stage IV), 55 patients were in the test group receiving chemotherapy according to plasma gene detection, and 9 patients were in the control. The median overall survival of test group was 15.5 months (95% CI = 10.1 to 20.9 months), the progress free survival was 9.1 months (95% CI = 8.0 to 10.2 months), which were significant longer than the control (P = 0.047 for OS, P = 0.038 for PFS). The risk of mortality was higher in the control than patients treated according to the plasma gene detection (HR in the control = 2.34, 95% CI = 0.93 to 5.88, P = 0.071). Plasma mRNA expression levels mirror those in the tumor and can be used as promising predictive biomarkers to predict chemo-efficiency.

Plasma Mrna As Liquid Biopsy in Individualized Chemotherapy of Gastric Cancer